A groundbreaking study from Washington University School of Medicine in St. Louis is poised to redefine our understanding of how prescription stimulant medications, widely used to treat attention deficit hyperactivity disorder (ADHD), exert their effects on the brain. Challenging a long-held paradigm that these drugs directly target brain regions associated with attention, the research, led by Benjamin Kay, MD, PhD, an assistant professor of neurology, and Nico U. Dosenbach, MD, PhD, the David M. & Tracy S. Holtzman Professor of Neurology, suggests that stimulants primarily influence brain systems governing reward and wakefulness. This shift in understanding has profound implications for diagnosis, treatment strategies, and the broader management of ADHD, particularly in children.
The Traditional View Versus a New Paradigm
For decades, the prevailing scientific and clinical belief has been that stimulant medications like Ritalin and Adderall improve ADHD symptoms by directly enhancing the activity of attentional networks in the brain, particularly those involving dopamine and norepinephrine in the prefrontal cortex. This region is crucial for executive functions, including focus, planning, and impulse control. The rationale was straightforward: by boosting neurotransmitter levels in these areas, stimulants would empower individuals with ADHD to exert more voluntary control over their attention, thereby reducing distractibility and improving concentration. This understanding has underpinned clinical practice and patient education for generations.
However, the new research, published on December 24, 2025, in the prestigious journal Cell, presents compelling evidence that this long-standing explanation may be incomplete, if not entirely misdirected. Instead, the study indicates that stimulants operate by making individuals feel more alert and more intrinsically interested in the tasks at hand. Rather than directly sharpening the cognitive lens of attention, these medications appear to increase overall engagement with activities. Furthermore, the researchers observed patterns of brain activity that strikingly resembled the effects of a good night’s sleep, suggesting stimulants might counteract the neural signatures typically associated with sleep deprivation.
Dr. Benjamin Kay, who also treats patients at St. Louis Children’s Hospital, articulated the significance of this finding: "I prescribe a lot of stimulants as a child neurologist, and I’ve always been taught that they facilitate attention systems to give people more voluntary control over what they pay attention to. But we’ve shown that’s not the case. Rather, the improvement we observe in attention is a secondary effect of a child being more alert and finding a task more rewarding, which naturally helps them pay more attention to it." This statement marks a pivotal moment, signaling a potential paradigm shift in both the scientific conceptualization and clinical application of ADHD treatments.
Prevalence of ADHD and Medication Use in the United States
ADHD is a neurodevelopmental disorder characterized by persistent patterns of inattention, hyperactivity, and impulsivity that interfere with functioning or development. It is one of the most commonly diagnosed childhood neurodevelopmental disorders. In the United States, the prevalence of ADHD has seen a notable increase over the past few decades, driven by improved diagnostic criteria, increased awareness, and potentially broader diagnostic thresholds. According to the Centers for Disease Control and Prevention (CDC), an estimated 6.1 million children aged 2-17 years (9.4%) have ever been diagnosed with ADHD. Among these, approximately 62% were taking medication for ADHD in 2016. The article specifically highlights that an estimated 3.5 million children ages 3 to 17 currently take medication for ADHD, a figure that has steadily risen in parallel with the increase in diagnoses. This widespread use underscores the critical importance of understanding the precise mechanisms of these medications.
Methodology: Unveiling Brain Activity Through fMRI
To scrutinize how stimulants influence the brain, the research team leveraged resting state functional MRI (fMRI) data from an extensive cohort of 5,795 children, aged 8 to 11, who are participants in the Adolescent Brain Cognitive Development (ABCD) Study. The ABCD Study is an ambitious, long-term, multisite project tracking the brain development of over 11,000 children across the U.S., including a significant site at WashU Medicine. It is the largest study of its kind, designed to shed light on how various factors, from genetics to environment, influence brain development and child health outcomes.
Resting state fMRI is a non-invasive neuroimaging technique that measures spontaneous brain activity when an individual is not engaged in a specific task. By observing patterns of brain connectivity—how different brain regions communicate with each other—researchers can infer the underlying functional organization of the brain. In this study, the team meticulously compared brain connectivity in children who had taken prescription stimulants on the day of their fMRI scan with those who had not.
The findings were striking and consistent: children who had taken stimulants exhibited demonstrably stronger activity in brain regions robustly associated with arousal and wakefulness. These areas include the brainstem and thalamic nuclei, which play crucial roles in regulating the sleep-wake cycle and overall alertness. Concurrently, the scans revealed heightened activity in regions involved in predicting the potential reward of an activity, such as components of the mesolimbic dopamine pathway, often referred to as the brain’s "reward circuit." Crucially, in contrast to the traditional hypothesis, the fMRI scans did not show notable increases in activity within regions classically identified as primary attention networks, such as the dorsolateral prefrontal cortex. This absence of direct engagement with traditional attention centers strongly supports the new proposed mechanism.
Validation in Adults: Reinforcing the Findings
To further validate their observations and ensure the findings were not exclusive to the pediatric population or the specific methodologies of the ABCD study, the researchers conducted a smaller, targeted study. This involved five healthy adults who did not have ADHD and did not typically take stimulant medications. Each participant underwent resting state fMRI scans both before and after receiving a single dose of a stimulant. This within-subject design allowed the research team to precisely track changes in brain connectivity induced by the medication. The results mirrored those from the larger ABCD study: the stimulants consistently activated reward and arousal networks, rather than the networks traditionally associated with direct attention. This confirmation in a controlled adult cohort strengthens the robustness and generalizability of the findings.
Dr. Nico Dosenbach elaborated on the functional implications: "Essentially, we found that stimulants pre-reward our brains and allow us to keep working at things that wouldn’t normally hold our interest — like our least favorite class in school, for example." He further explained that by making tasks that are typically difficult to focus on feel more rewarding, stimulants can help children, and adults, persist with both challenging and repetitive activities. This mechanism offers a novel explanation for how these drugs improve academic performance and task completion.
Solving a Paradox: Stimulants and Hyperactivity
The new understanding also offers a compelling explanation for how stimulants effectively treat hyperactivity, a symptom that previously presented a conceptual paradox. "These results also provide a potential explanation for how stimulants treat hyperactivity, which previously seemed paradoxical," Dosenbach added. "Whatever kids can’t focus on — those tasks that make them fidgety — are tasks that they find unrewarding. On a stimulant, they can sit still better because they’re not getting up to find something better to do." This insight suggests that by elevating the perceived reward value of less engaging activities, stimulants reduce the internal drive to seek more stimulating alternatives, thereby diminishing fidgeting and restless behavior. It reframes hyperactivity not as a direct failure of motor control, but as a consequence of insufficient engagement with unrewarding tasks.
Clinical Outcomes: Academic Performance and Cognitive Benefits
The study also delved into the real-world impact of stimulant use. Within the vast dataset of the ABCD study, children with ADHD who were taking stimulant medications consistently demonstrated higher school grades, as reported by their parents, and performed better on standardized cognitive tests compared to children with ADHD who were not on stimulants. These improvements were particularly pronounced in children presenting with more severe ADHD symptoms, indicating a clear therapeutic benefit.
However, a critical nuance emerged regarding the role of sleep. The benefits of stimulants were not universally observed across all participants. Among children who consistently slept less than the recommended nine or more hours per night, those who took stimulants achieved better grades than their sleep-deprived counterparts who did not receive medication. This suggests that stimulants might, in some contexts, compensate for the cognitive deficits induced by insufficient sleep. Conversely, stimulants were not associated with improved performance in neurotypical children who were already getting adequate sleep. The reasons for these neurotypical children taking stimulant medications were not explicitly detailed, but their inclusion provided an important control group. Overall, the link between stimulants and improved cognitive performance appeared to be robust primarily in children diagnosed with ADHD or in those experiencing chronic sleep deprivation.
Dr. Dosenbach highlighted this remarkable observation: "We saw that if a participant didn’t sleep enough, but they took a stimulant, the brain signature of insufficient sleep was erased, as were the associated behavioral and cognitive decrements." This finding underscores the powerful effect stimulants have on the brain’s arousal systems, essentially mimicking the restorative effects of adequate sleep on cognitive function.
The Peril of Masking Sleep Deprivation: Long-Term Consequences
While the ability of stimulants to ameliorate the cognitive effects of poor sleep might seem beneficial in the short term, the researchers issued a strong caution regarding potential long-term consequences. Masking the symptoms of sleep deprivation, rather than addressing its root cause, carries significant health risks.
"Not getting enough sleep is always bad for you, and it’s especially bad for kids," Dr. Kay emphasized. Children who are chronically overtired can exhibit a constellation of symptoms that closely resemble ADHD, including difficulty sustaining attention in class, increased impulsivity, emotional dysregulation, and declining academic performance. In such cases, sleep deprivation, rather than ADHD, might be the primary underlying issue, potentially leading to misdiagnosis. If stimulant medications are prescribed in these instances, they might appear to "help" by mimicking some of the positive effects of adequate sleep, while simultaneously allowing the child to remain exposed to the cumulative, detrimental effects of chronic sleep loss. These long-term harms can include impaired immune function, metabolic dysfunction, mood disorders, and continued cognitive deficits.
This critical insight compels clinicians to broaden their diagnostic approach. Dr. Kay urged medical professionals to proactively consider and thoroughly evaluate sleep quality during ADHD assessments and to explore effective strategies to improve sleep hygiene and duration when deficiencies are identified. This holistic approach ensures that the true underlying issues are addressed, rather than merely treating symptoms.
Broader Implications and Future Research Directions
The findings from Washington University School of Medicine carry significant implications across several domains:
- Refined Diagnostic Protocols: The research strongly advocates for incorporating comprehensive sleep evaluations into the diagnostic process for ADHD. Distinguishing between ADHD and sleep deprivation-induced symptoms is crucial for accurate diagnosis and appropriate treatment.
- Personalized Treatment Strategies: A deeper understanding of stimulant mechanisms could pave the way for more personalized treatment approaches. If a child’s primary challenge is related to task engagement or low arousal, understanding this could inform medication choice or adjunctive therapies.
- Rethinking Patient Education: Clinicians can now explain the effects of stimulants to patients and parents in a more nuanced way, emphasizing increased alertness and interest rather than direct attention enhancement. This could manage expectations and foster a more informed approach to treatment.
- Novel Therapeutic Targets: Identifying reward and wakefulness systems as primary targets opens new avenues for pharmaceutical research, potentially leading to the development of novel ADHD medications with different pharmacological profiles.
- Ethical Considerations: The ability of stimulants to mask sleep deprivation raises ethical questions about their use, particularly in academic or competitive environments where individuals might use them to compensate for insufficient rest rather than addressing the underlying health issue.
Drs. Dosenbach and Kay stressed that their findings also highlight the urgent need for further research into the long-term effects of stimulant use on the developing brain. They hypothesize that stimulants might play a restorative role by activating the brain’s glymphatic system—a waste-clearing mechanism that is most active during sleep—even during wakefulness. However, this potential benefit must be weighed against the significant risk that these medications could inadvertently cause lasting harm if they are chronically employed to compensate for ongoing sleep deficits. The long-term impact of consistently altering the brain’s natural sleep-wake and reward cycles remains an area requiring extensive investigation.
Conclusion
The study "Stimulant medications affect arousal and reward, not attention networks," published by Kay et al. in Cell on December 24, 2025, represents a pivotal moment in ADHD research. By meticulously analyzing brain activity patterns, researchers from Washington University School of Medicine in St. Louis have effectively challenged a foundational belief about how prescription stimulants work. Their findings suggest that these medications primarily enhance wakefulness and increase the perceived reward of tasks, leading to improved engagement and a secondary effect on attention, rather than directly targeting attentional networks. This paradigm shift not only deepens our scientific understanding of ADHD pathophysiology but also prompts a critical re-evaluation of diagnostic practices, treatment strategies, and the broader management of ADHD, particularly emphasizing the indispensable role of adequate sleep for healthy brain development and function. The implications for clinicians, parents, and individuals with ADHD are profound, promising a future of more informed and potentially more holistic care.
Publication Details:
Kay BP, Wheelock MD, Siegel JS, Raut R, Chauvin RJ, Metoki A, Rajesh A, Eck A, Pollaro J, Wang A, Suljic V, Adeyemo B, Baden NJ, Scheidter KM, Monk JS, Whiting FI, Ramirez-Perez N, Krimmel SR, Shinohara RT, Tervo-Clemmens B, Hermosillo RJM, Nelson SM, Hendrickson TJ, Madison T, Moore LA, Miranda-Domínguez O, Randolph A, Feczko E, Roland JL, Nicol GE, Laumann TO, Marek S, Gordon EM, Raichle ME, Barch DM, Fair DA, and Dosenbach NUF. Stimulant medications affect arousal and reward, not attention networks. Cell. Dec. 24, 2025. DOI: 10.1016/j.cell.2025.11.039
Funding Acknowledgment:
This work was supported by NIH grants NS140256 (EMG, NUFD), EB029343 (MW), MH121518 (SM), MH129493 (DMB), NS123345 (BPK), NS098482 (BPK), DA041148 (DAF), DA04112 (DAF), MH115357 (DAF), MH096773 (DAF and NUFD), MH122066 (EMG, DAF, and NUFD), MH121276 (EMG, DAF, and NUFD), MH124567 (EMG, DAF, and NUFD), and NS129521 (EMG, DAF, and NUFD); by the National Spasmodic Dysphonia Association (EMG); by Mallinckrodt Institute of Radiology pilot funding (EMG); by the Andrew Mellon Predoctoral Fellowship from the Dietrich School of Arts & Sciences, University of Pittsburgh (BTC); and by the Extreme Science and Engineering Discovery Environment (XSEDE) Bridges at the Pittsburgh Supercomputing Center through allocation TG-IBN200009 (BTC). Computations were performed using the facilities of the Washington University Research Computing and Informatics Facility (RCIF). The RCIF has received funding from NIH S10 program grants: 1S10OD025200-01A1 and 1S10OD030477-01. This article reflects the view of the authors and may not reflect the opinions or views of the NIH or ABCD consortium investigators.
